CN104341416B - 蛋白酪氨酸激酶抑制剂及其应用 - Google Patents

蛋白酪氨酸激酶抑制剂及其应用 Download PDF

Info

Publication number: CN104341416B
Authority: CN; China
Prior art keywords: amino; alkyl; methyl; compound; pyridine
Prior art date: 2013-07-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN201310329248.8A

Other languages

English (en)

Chinese (zh)

Other versions

CN104341416A (zh

Inventor

王勇

赵立文

陈宏雁

王德忠

刘阳

毕胜

高毅平

张迪

张仓

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nanjing Sanhome Pharmaceutical Co Ltd

Original Assignee

Nanjing Sanhome Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-31

Filing date

2013-07-31

Publication date

2017-03-29

2013-07-31 Application filed by Nanjing Sanhome Pharmaceutical Co Ltd filed Critical Nanjing Sanhome Pharmaceutical Co Ltd

2013-07-31 Priority to CN201310329248.8A priority Critical patent/CN104341416B/zh

2014-07-30 Priority to PCT/CN2014/083284 priority patent/WO2015014283A1/fr

2014-07-31 Priority to TW103126236A priority patent/TWI546304B/zh

2015-02-11 Publication of CN104341416A publication Critical patent/CN104341416A/zh

2017-03-29 Application granted granted Critical

2017-03-29 Publication of CN104341416B publication Critical patent/CN104341416B/zh

Status Active legal-status Critical Current

2033-07-31 Anticipated expiration legal-status Critical

Links

0 CCC=C(C=C)C(CNC(CC)=CCC=C(CN1CCCN(C)CCC1)C=*)=O Chemical compound CCC=C(C=C)C(CNC(CC)=CCC=C(CN1CCCN(C)CCC1)C=*)=O 0.000 description 6
JOXGDNSTOGOWKM-UHFFFAOYSA-N CCCN(C)CCNCc(c(C(F)(F)F)c1)ccc1NC(c1cc(C#CC2=C(C)[n]3nc(N(C)C)nc3CC2)c(C)cc1)=O Chemical compound CCCN(C)CCNCc(c(C(F)(F)F)c1)ccc1NC(c1cc(C#CC2=C(C)[n]3nc(N(C)C)nc3CC2)c(C)cc1)=O JOXGDNSTOGOWKM-UHFFFAOYSA-N 0.000 description 1
RASZUSKDUKICSI-UHFFFAOYSA-N Cc(c(C#Cc1ccc[n]2nc(NC)nc12)c1)ccc1C(Nc1ccc(CN2CCN(C)CC2)c(C(F)(F)F)c1)=O Chemical compound Cc(c(C#Cc1ccc[n]2nc(NC)nc12)c1)ccc1C(Nc1ccc(CN2CCN(C)CC2)c(C(F)(F)F)c1)=O RASZUSKDUKICSI-UHFFFAOYSA-N 0.000 description 1
DBYMNQDLOULLJR-UHFFFAOYSA-N Cc(ccc(C(CNc1ccc(CN2CCN(C)CC2)c(C(F)(F)F)c1)=O)c1)c1C#C Chemical compound Cc(ccc(C(CNc1ccc(CN2CCN(C)CC2)c(C(F)(F)F)c1)=O)c1)c1C#C DBYMNQDLOULLJR-UHFFFAOYSA-N 0.000 description 1
VPJPOLAKEXJROI-UHFFFAOYSA-N Cc(ccc(C(Nc1cc(C(F)(F)F)c(CCC2=CCCN(C)CC2)cc1)=O)c1)c1C#Cc1c[n]2nc(N)nc2cc1C Chemical compound Cc(ccc(C(Nc1cc(C(F)(F)F)c(CCC2=CCCN(C)CC2)cc1)=O)c1)c1C#Cc1c[n]2nc(N)nc2cc1C VPJPOLAKEXJROI-UHFFFAOYSA-N 0.000 description 1
CMTDGUODVOOAOG-UHFFFAOYSA-N Cc(ccc(C(Nc1cc(C(F)(F)F)c(CN2CCN(C)CC2)cc1)=O)c1)c1C#Cc1c(C(F)(F)F)[n]2nc(NC)nc2cc1 Chemical compound Cc(ccc(C(Nc1cc(C(F)(F)F)c(CN2CCN(C)CC2)cc1)=O)c1)c1C#Cc1c(C(F)(F)F)[n]2nc(NC)nc2cc1 CMTDGUODVOOAOG-UHFFFAOYSA-N 0.000 description 1
UHNMOAIINYVSKV-UHFFFAOYSA-N Cc(ccc(C(Nc1cc(C(F)(F)F)c(CN2CCN(C)CC2)cc1)=O)c1)c1C#Cc1c[n]2nc(N)nc2cc1C Chemical compound Cc(ccc(C(Nc1cc(C(F)(F)F)c(CN2CCN(C)CC2)cc1)=O)c1)c1C#Cc1c[n]2nc(N)nc2cc1C UHNMOAIINYVSKV-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

CN201310329248.8A 2013-07-31 2013-07-31 蛋白酪氨酸激酶抑制剂及其应用 Active CN104341416B (zh)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CN201310329248.8A CN104341416B (zh)	2013-07-31	2013-07-31	蛋白酪氨酸激酶抑制剂及其应用
PCT/CN2014/083284 WO2015014283A1 (fr)	2013-07-31	2014-07-30	Inhibiteur de protéine tyrosine kinase et application associée
TW103126236A TWI546304B (zh)	2013-07-31	2014-07-31	Protein tyrosine kinase inhibitors and their use

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN201310329248.8A CN104341416B (zh)	2013-07-31	2013-07-31	蛋白酪氨酸激酶抑制剂及其应用

Publications (2)

Publication Number	Publication Date
CN104341416A CN104341416A (zh)	2015-02-11
CN104341416B true CN104341416B (zh)	2017-03-29

Family

ID=52431006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201310329248.8A Active CN104341416B (zh)	2013-07-31	2013-07-31	蛋白酪氨酸激酶抑制剂及其应用

Country Status (3)

Country	Link
CN (1)	CN104341416B (fr)
TW (1)	TWI546304B (fr)
WO (1)	WO2015014283A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106749278B (zh) *	2016-12-29	2019-03-26	天津国际生物医药联合研究院	三氮唑类化合物的制备及其应用
WO2019043635A1 (fr)	2017-09-01	2019-03-07	Richter Gedeon Nyrt.	Composés inhibiteurs de l'activité de d-amino acide oxydase
TW202039486A (zh)	2018-12-14	2020-11-01	南韓商柳韓洋行股份有限公司	***并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103044432A (zh) *	2005-12-23	2013-04-17	阿里亚德医药股份有限公司	双环杂芳基化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012139027A1 (fr) *	2011-04-07	2012-10-11	Ariad Pharmaceuticals, Inc.	Procédés et compositions pour le traitement de maladies neurodégénératives
BR112013024169A2 (pt) *	2011-04-07	2016-12-06	Ariad Pharma Inc	método para o tratamento e prevenção da doença de parkinson
RU2477723C2 (ru) *	2011-06-16	2013-03-20	Общество С Ограниченной Ответственностью "Фьюжн Фарма"	Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CN103421005A (zh) *	2012-05-16	2013-12-04	上海医药集团股份有限公司	具有抗肿瘤活性的乙炔衍生物
CN103848829B (zh) *	2012-11-28	2017-04-12	南京圣和药业股份有限公司	杂芳基炔烃化合物及其应用

2013
- 2013-07-31 CN CN201310329248.8A patent/CN104341416B/zh active Active
2014
- 2014-07-30 WO PCT/CN2014/083284 patent/WO2015014283A1/fr active Application Filing
- 2014-07-31 TW TW103126236A patent/TWI546304B/zh not_active IP Right Cessation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103044432A (zh) *	2005-12-23	2013-04-17	阿里亚德医药股份有限公司	双环杂芳基化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against Imatinib.《Journal of Medicinal Chemistry》.2013,第56卷(第3期),第879-894页. *
Xiaomei Ren et al..Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated Breakpoint Cluster Region&#8722 *

Also Published As

Publication number	Publication date
CN104341416A (zh)	2015-02-11
TWI546304B (zh)	2016-08-21
WO2015014283A1 (fr)	2015-02-05
TW201504239A (zh)	2015-02-01

Similar Documents

Publication	Publication Date	Title
JP5974124B2 (ja)	2016-08-23	キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
CN105461714B (zh)	2017-11-28	并环类pi3k抑制剂
CN104379583B (zh)	2016-06-08	作为wnt信号传导抑制剂的化合物、组合物及其应用
CN102887895B (zh)	2016-08-24	吡啶并嘧啶类mTOR抑制剂
CN104797581B (zh)	2017-02-15	杂芳基炔烃化合物及其应用
CN108137593A (zh)	2018-06-08	新型蛋白激酶抑制剂的制备和用途
CN101611025A (zh)	2009-12-23	5,6-环化的吲哚衍生物及其使用方法
CN106488910A (zh)	2017-03-08	Kras g12c的抑制剂
CA2922352A1 (fr)	2015-03-05	Composition pharmaceutique renfermant un compose pyrimidine comme ingredient actif
CN104395315A (zh)	2015-03-04	作为LRRK2抑制剂的新的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
CN105315285A (zh)	2016-02-10	2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
CN103857288A (zh)	2014-06-11	作为激酶抑制剂的氨基-喹啉
CN105143228A (zh)	2015-12-09	[1,2,4]***并[4,3-a]吡啶类衍生物，其制备方法或其在医药上的应用
CN114555588A (zh)	2022-05-27	作为axl抑制剂的喹唑啉类化合物
CN106232118A (zh)	2016-12-14	杂芳族化合物及其作为多巴胺d1配体的用途
CN104341416B (zh)	2017-03-29	蛋白酪氨酸激酶抑制剂及其应用
WO2014209727A1 (fr)	2014-12-31	Composés benzofuranes substitués et leurs méthodes d'utilisation pour le traitement de maladies virales
CN109942556A (zh)	2019-06-28	嘧啶酮化合物及其应用
CN103936762B (zh)	2016-02-24	吗啉并喹啉类化合物，其制备方法和用途
CN107001317B (zh)	2019-05-24	高选择性取代嘧啶类pi3k抑制剂
CN104418867B (zh)	2016-12-28	作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
CN105541792B (zh)	2018-03-13	多环类pi3k抑制剂
CN104974132A (zh)	2015-10-14	多取代的吡啶化合物、制备方法、用途及药物组合物
CN107235931A (zh)	2017-10-10	新型嘧啶类抗肿瘤化合物及其制备方法与用途
CN105859684A (zh)	2016-08-17	一种稠环化合物、其制备方法和应用及其中间体化合物

Legal Events

Date	Code	Title
2015-02-11	C06	Publication
2015-02-11	PB01	Publication
2015-12-23	C10	Entry into substantive examination
2015-12-23	SE01	Entry into force of request for substantive examination
2017-03-29	GR01	Patent grant
2017-03-29	GR01	Patent grant